RaySearch Laboratories AB (publ) Interim Report January 1 - March 31, 2010

RaySearch Laboratories AB (publ) Interim Report January 1 - March 31, 2010

JANUARY 1 - MARCH 31, 2010 
• Net sales for the period totaled SEK 28.1 M (16.9) 
• Profit after tax was SEK 8.2 M (7.3), corresponding to earnings per share of
SEK 0.24 (0.21) 
• Operating profit totaled SEK 11.2 M (9.9)
• Cash flow was a negative SEK 1.8 M (positive: 8.7)
• RaySearch received FDA 510(k) clearance for RayStation® in the US

SIGNIFICANT EVENTS AFTER THE CLOSE OF THE PERIOD
•	The collaboration agreement with Varian was expanded in April 


“The year 2010 started favorably with a strong first quarter. Thanks to several
key product launches toward year-end 2009, revenues increased by 66 percent and
the number of licenses sold almost doubled. This means that the quarterly
revenues were the second highest ever for RaySearch,” says Johan Löf, CEO of
RaySearch. 

“It was an important milestone to receive 510(k) clearance from the FDA for our
treatment planning system RayStation®. This means that we can now market the
system in the US”, concludes Johan Löf.


FOR ADDITIONAL INFORMATION, CONTACT:

Johan Löf, CEO
Telephone: 08-545 061 30
johan.lof@raysearchlabs.com


ABOUT RAYSEARCH

RaySearch Laboratories is a medical technology company that develops advanced
software solutions for improved radiation therapy of cancer. RaySearch's
products are mainly sold through license agreements with leading partners such
as Philips, Varian, Siemens, Nucletron, IBA Dosimetry and TomoTherapy. To date,
15 products have been launched and RaySearch's software is used at some 1,500
clinics in more than 30 countries. In addition, existing license agreements
cover more than 15 other products that are scheduled to be launched in the
coming years. RaySearch was founded in 2000 as a spin-off from Karolinska
Institutet in Stockholm and the company is listed in the Small Cap segment on
NASDAQ OMX Stockholm. 

For more information about RaySearch, visit www.raysearchlabs.com.